Summary
Whilst severe asthma has classically been categorized as a predominantly Th2-driven pathology, there has in recent years been a paradigm shift with the realization that it is a heterogeneous disease that may manifest with quite disparate underlying inflammatory and remodelling profiles. A subset of asthmatics, particularly those with a severe, corticosteroid refractory disease, present with a prominent neutrophilic component. Given the potential of neutrophils to impart extensive tissue damage and promote inflammation, it has been anticipated that these cells are closely implicated in the underlying pathophysiology of severe asthma. However, uncertainty persists as to why the neutrophil is present in the asthmatic lung and what precisely it is doing there, with evidence supporting its role as a protagonist of pathology being primarily circumstantial. Furthermore, our view of the neutrophil as a primitive, indiscriminate killer has evolved with the realization that neutrophils can exhibit a marked anti-inflammatory, pro-resolving and wound healing capacity. We suggest that the neutrophil likely exhibits pleiotropic and potentially conflicting roles in defining asthma pathophysiology-some almost certainly detrimental and some potentially beneficial-with context, timing and location all critical confounders. Accordingly, indiscriminate blockade of neutrophils with a broad sword approach is unlikely to be the answer, but rather we should first seek to understand their complex and multifaceted roles in the disease state and then target them with the same subtleties and specificity that they themselves exhibit.
| INTRODUCTION
The most recently revised estimates by the Global Burden Disease study suggest that as many as 340 million individuals suffer from asthma worldwide, with a substantial burden of disability and around 180 000 deaths annually attributed to the disease. This epidemic of asthma is thought to be increasing in prevalence by 50% every decade and is a global affliction affecting individuals of all ages and backgrounds. It is estimated that between 5% and 10% of asthmatics suffer from a disease that could be classified as severe, 1 though recent studies have suggested that prevalence could be yet lower still. 2 Despite their relatively low numbers, this subset of patients represent a particularly problematic group for the healthcare practitioner as they exhibit near daily symptoms, persistent airflow obstruction, frequent and severe exacerbations and, most importantly, are refractory to current gold standards for asthma treatment.
Whilst asthma had classically been categorized as a predominantly Th2-mediated inflammation, there has in recent years been paradigm shift, and it is becoming increasingly apparent that severe asthma represents a heterogeneous disease rather than a homogeneous pathology and presentation. Consequently, there has been the realization that it is critical to recognize severe asthma phenotypes with distinct pathogenesis and subsequently define unique therapeutic targets to provide a personalized strategy for treatment. It is now evident that a neutrophilic infiltrate is a prominent feature of the inflammation observed in a subset of asthmatics, being particularly 
| OUR EVOLVING VIE W OF NEUTROPHILS IN INFLAMMATION
Neutrophils are indispensable components of the host's immune response, being readily recruited to the site of infection before killing the invading micro-organisms with an array of toxic products. 3, 4 The indiscriminate action of these products, however, means that neutrophils also cause significant bystander or "collateral" tissue damage and thus an over-exuberant or persistent neutrophilic inflammation is implicated in the pathologies of an array of diseases. 5, 6 There has therefore been the conventional view of neutrophils as crude and primitive suicide killers that arrive at a site of inflammation, releasing their payload and killing all that stands in their way. However, it is becoming increasingly apparent that this view does not do justice to a cell that at times can exhibit an amazing sophistication, versatility and complexity. [7] [8] [9] A common misconception is that neutrophils are short lived, isolated and terminally differentiated cells that arrive at the site of inflammation before throwing out their pre-formed products and being replaced by more specialized immune counterparts. In reality, neutrophils are able to sense their localized environment, being receptive to the presence of pathogens, tissue damage and signals derived from localized cells. [10] [11] [12] [13] [14] [15] This information is integrated into a central algorithm informing the neutrophil and defining its ensuing behaviour. 
| TH E H ETE ROGENE ITY OF HUMAN

ASTHMA
Asthma has classically been regarded as a Th2-driven pathophysiological condition. This view originally emanated from analysis of limited patient samples and from researchers working with mouse models of allergic asthma whom reported an allergic, eosinophilic and Th2-mediated disease. [55] [56] [57] However, the disappointing results attained from clinical trials focused at specifically targeting these Th2 pathways, the realization that some patients with severe asthma presented with an underlying pathology devoid of eosinophils and that the efficacy of corticosteroids was dependent upon the type of underlying inflammation, ultimately led to a rethink of the notion of asthma as a single disease with a Th2 aetiology. 55, [58] [59] [60] [61] The development of more efficient and safer sampling methods has in turn facilitated a more extensive analysis and understanding of the characteristic pathologies of human disease. Accordingly, asthma has undergone a paradigm shift, and it is becoming increasingly apparent that severe asthma represents a heterogeneous disease rather than manifesting as a homogeneous pathology and presentation. 55, 57, 62 Consequently, there has been the realization that it is critical to recognize severe asthma phenotypes with distinct pathogenesis and subsequently define unique therapeutic targets to provide a personalized strategy for treatment. 63 The heterogeneity of the disease has made classification difficult for the medical practitioner, and this coupled with misconceptions about the relation between different aspects of severe asthma, along with underlying comorbidities and confounders, have hindered treatment strategies and novel drug development.
Non-Th2 inflammation, characterized by low eosinophilia, is observed in a substantial proportion of asthmatics, although considerably less is understood about this patient group and the underlying causes of disease. These individuals can exhibit highly variable inflammatory and physiological profiles 57, 64 and often respond poorly to corticosteroids. 65, 66 Studies aimed at dissecting the inflammatory pattern of these patients have revealed a significant innate immune component, with increased levels innate cytokines, such as TNF-α and IL- those with severe asthma on high dose corticosteroids. 73 A neutrophilic component is now increasingly being recognized as a prominent feature of the pulmonary infiltrate in some subsets of asthmatic patients. [55] [56] [57] 62, 73, 74 Neutrophilic asthma as a phenotype has generally been described as those patients with high sputum neutrophil counts ranging from 40% to 76% of cells. However, it must be acknowledged that neutrophils represent a prominent population in blood and sputum of all asthmatics and as such may also be contributing to disease progression more broadly. Green et al 60 identified a subgroup of 60 patients with higher neutrophil counts that were less likely to be atopic within a cohort of 259 adult asthmatics. Subsequently, the same research group identified that patients with high sputum neutrophil counts but non-differential eosinophil counts had lower FEV 1 measurements post-bronchodilator administration. 75 Gupta et al 76 Djukanovic and colleagues demonstrated that airway neutrophils in severe asthmatics displayed a pro-survival capacity with reduced numbers of apoptotic neutrophils compared to mild asthmatics and healthy control patients. 86 Subsequently, this group showed that profound EGF signalling in the epithelial cells of severe asthmatics seemingly induced neutrophil survival by inducing the release of neutrophil chemokines and survival factors such as IL-6, IL-8, GM-CSF and TNF-α. 87 Fahy and colleagues reported increased sputum neutrophils post-asthma exacerbations, 81 with a subsequent study observing increased neutrophil infiltration in bronchial biopsies of patients with sudden-onset fatal asthma. 88 Additional studies have also described increased BAL neutrophils in asthmatic patients requiring ventilation due to exacerbations. 89 Likewise, sputum neutrophilia and heightened IL-8 concentrations were observed in children admitted to hospital emergency departments post-exacerbation. 90 Neutrophil infiltration has also been observed in patients with occupational asthma after being challenged with agents such as toluene diisocyanate. 91 With it now apparent that there is a need to tailor therapies to specific sub-phenotypes of patients with severe asthma, Whilst IL-17 has no direct effect on neutrophil function, it is able to indirectly promote neutrophil recruitment by triggering the release of neutrophil chemokines from structural cells 108, 109 and is also capable of promoting neutrophil survival and activation. 110, 111 Animal models of allergic airway disease have highlighted the importance of IL-17 producing cells in the recruitment of neutrophils and induction of AHR. 108, 112 In a steroid-insensitive Th-17 cell adoptive transfer model of allergic airways disease, neutrophil depletion reduced airway inflammation and rescued lung compliance but did not improve AHR to methacholine. 113 Whilst the physiological relevance of some of these models to human disease and the specificity by which neutrophils are targeted can be debated, there is enough to argue that neutrophils can contribute to asthma pathophysiology. Nonetheless, detailed mechanisms underlying any detrimental effects of neutrophils in asthma are predominantly speculative.
As already noted, products released by neutrophils, such as proteases and reactive oxygen species, possess a marked capacity to cause direct non-specific tissue damage and thus it is easy to rationalize the pathological contribution of these cells when deregulated in the asthmatic lung. This likely represents an oversimplified view, however, of the probable multifaceted and complex potential of neutrophils in allergic airways disease. As previously discussed, neutrophils release a plethora of mediators that, directly or indirectly, drive the migration, activation, maturation, differentiation and survival of both stromal cells and leucocytes. 114 An abundance of literature highlights the augmented levels of MMP-9 in the asthmatic lung, and although this protease can be derived from a multitude of cells, it has been found to be almost entirely neutrophil derived. 115 BAL, sputum, exhaled breath condensates and tissue biopsy levels of MMP-9 have all been described to be elevated in asthmatics, with levels being reportedly refractory to corticosteroids and correlating with the extent of cellular infiltrate and the severity of disease. Lactoferrin, derived from the secondary granules of neutrophils, has been reported to be elevated in sputum of asthmatics that readily expectorate relative to healthy controls. 140 Furthermore, augmented lactoferrin expression is seen in lung tissue sections from individuals with fatal slow-onset and sudden-onset asthma relative to non-asthmatic controls. 141 Lactoferrin functions as an important mediator of host defence against bacterial and fungal pathogens by sequestering iron. However, it is now acknowledged that lactoferrin is a multifunctional protein with an array of immunoregulatory functions pertinent to the establishment of an inflammatory response, with roles ascribed in antibody synthesis, pro-inflammatory cytokine production, complement activation, T-cell proliferation and NK cell cytoxicity. 142 It has been postulated that lactoferrin in the asthmatic airways may have a role in eosinophil activation, with studies highlighting its capacity to promote O 2 -production, degranulation and cysteinyl leukotriene release. 143 Although this list of neutrophil products is not meant to be exhaustive, it highlights how neutrophilspecific products can directly drive tissue damage and many of the hallmark features of asthma pathophysiology.
| NEUTROPH ILS IN ASTHMA: NECESSARILY AN EVIL?
Whilst a strong case can certainly be made for a pathological role for neutrophils in asthma, the evidence is by no means conclusive.
Although clinical data highlight the presence of neutrophils in severe, poorly controlled asthma, the presence does not naturally equate to causality. Indeed the majority of the evidence is largely acting with its signal transducing receptor IL-1R1. 41 Furthermore, neutrophils release IL-1RA, particularly in response to anti- 53 Thus, perhaps the traditional misconception that neutrophils can only be pathological should be disregarded.
As discussed above, there is strong circumstantial evidence that MMP-9 is elevated in asthma and may contribute to pathology of disease; however, two studies in animal models have suggested that MMP-9 may actually serve a positive role in limiting and resolving allergic airways disease. 159, 160 Another study has demonstrated a positive role for neutrophil derived proteases in the destruction of mucus plugs that are such an important cause of airway obstruction in severe asthma. 161 In keeping with these studies, it has recently been shown that the presence of neutrophil chemokines was actually associated with better clinical outcomes in a subset of patients with severe neutrophilic asthma. 113 Furthermore, we have shown that a proportion of children with severe therapy resistant asthma (STRA) have increased intraepithelial neutrophils within their lungs and higher IL-17RA, which correlated with better lung function. 162 Together these studies suggest that it is possible that neutrophils may play a beneficial role in the pathophysiology of asthma and that context and location may be important in defining their contribution to the disease state.
| CONCLUSIONS
Given that neutrophils are armed with a toxic arsenal capable of eliciting profound tissue destruction and the clear indication that neutrophils are a prominent inflammatory cell in a subset of asthmatics with an often severe and corticosteroid refractory phenotype; then, it is unsurprising that the neutrophil has been cast as the villain that drives disease pathology and that should be therapeutically targeted at all costs. Whilst this viewpoint is not without merit, we should discard the outdated misconception of neutrophils as primitive, primarily pathological cells. Instead, we should acknowledge a cell that at times can exhibit a pronounced awareness and plasticity, an impressive and broad biosynthetic capacity, and a marked potential to influence and shape the inflammatory environment to which it enters. Furthermore, we should consider the neutrophil in the asthmatic lung as a poten- 
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